Mineralys Therapeutics (MLYS) Non Operating Income (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Non Operating Income data on file, last reported at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 168.02% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $19.7 million (up 51.99% YoY), and the FY2025 full-year result was $16.0 million, up 9.36% from the prior year.
• Non Operating Income declined to $6.0 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $6.0 million in Q4 2025 to a low of $745000.0 in Q3 2022.
• A 5-year average of $3.4 million and a median of $3.5 million in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income soared 371.54% in 2023 and plunged 41.89% in 2025, its largest moves.
• Tracing MLYS's Non Operating Income over 5 years: stood at $935000.0 in 2022, then surged by 255.19% to $3.3 million in 2023, then dropped by 15.21% to $2.8 million in 2024, then surged by 114.7% to $6.0 million in 2025, then decreased by 0.74% to $6.0 million in 2026.
• Business Quant data shows MLYS's Non Operating Income at $6.0 million in Q1 2026, $6.0 million in Q4 2025, and $4.2 million in Q3 2025.